Deere (DE) FY26 production and precision ag sales are now expected to decline c. 10%, towards the bottom of prior guidance; op. narrowed to 11-12%; further industry softening in South America and Europe drove the revision
Newsquawk Staff ·
Deere (DE) FY26 production and precision ag sales are now expected to decline c. 10%, towards the bottom of prior guidance; op. narrowed to 11-12%; further industry softening in South America and Europe drove the revision.
What it means
Guidance revisions framed as a move to the low end of a prior range are a familiar pattern in the ag equipment cycle: they usually mark the point where a downturn that began in large-ticket crop machinery broadens across regions, and here the revision originates in South America and Europe rather than the core North American replacement cycle. The distinction that matters for the peer set is between production ag and precision ag: weakness concentrated in production equipment points to farm income and fleet age, while a downgrade touching precision attachments signals that the technology-upgrade cycle, historically the more resilient leg, is also being deferred. Margin guidance that narrows rather than collapses suggests the down-cycle playbook is operating, with cost actions and pricing discipline absorbing part of the volume decline, as has been Deere's form in prior troughs. Downstream reads typically extend to engine suppliers, parts distributors and rival OEMs, where order books tend to be revised with a lag. The follow-ons worth tracking are dealer inventory commentary, used-equipment pricing, and whether further regional softening appears in interim updates, since cycles of this kind have historically troughed only after guidance has been cut more than once.
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation
- American Express (AXP) to cut 5% of jobs
Related headlines
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM1 hour ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years2 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months2 hours ago
- American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)3 hours ago
- Booz Allen (BAH) Q2 2026 (USD): Adj. EPS 1.76 (exp. 1.48), Revenue 2.80bln (prev. 2.81bln)3 hours ago
- SLB (SLB) Q3 2026 (USD): adj. EPS 0.64 (exp. 0.62), Revenue 9.45bln (exp. 9.27bln)3 hours ago
- Citi (C) has been granted approval by China for its securities unit6 hours ago
- Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand14 hours ago
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT16 hours ago
- Newmont (NEM) says production growth is expected to begin in 2027 following previously flagged 2026 trough, adds Q3 gold production was broadly flat sequentially as anticipated16 hours ago
- SpaceX (SPCX) in talks to access 80,000 cell sites for new network16 hours ago
- Google (GOOG) announces general availability of an Anthropic-managed deployment option for Claude models on Google Cloud17 hours ago
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE18 hours ago
- Gilead Sciences (GILD) entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited; deal valued at USD 1.27bln in upfront cash18 hours ago
- Newmont (NEM) Q3 2026 (USD): Adj. EPS 2.20 (exp. 2.06), Revenue 6.36bln (exp. 6.30bln), Adj. EBITDA 3.95bln (exp. 3.73bln)18 hours ago